Who are RSVpreF MDV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RSVpreF 120 µg, RSVpreF, RSV F vaccine with adjuvant, [89Zr]Zr-crefmirlimab berdoxam, Venetoclax; Rituximab, Hympavzi.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rsvpref-mdv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

RSVpreF MDV — Competitive Intelligence Brief

RSVpreF MDV (rsvpref-mdv) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Infectious Disease.

marketed Monoclonal antibody RSV F protein Infectious Disease Live · refreshed every 30 min

Target snapshot

RSVpreF MDV (rsvpref-mdv) — Pfizer Inc..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RSVpreF MDV TARGET	rsvpref-mdv	Pfizer Inc.	marketed	Monoclonal antibody	RSV F protein
RSVpreF 120 µg	rsvpref-120-g	Pfizer	marketed	Recombinant subunit vaccine	Prefusion form of the RSV F protein
RSVpreF	rsvpref	Pfizer	marketed	Monoclonal antibody	RSV F protein
RSV F vaccine with adjuvant	RSV F vaccine with adjuvant	Novavax	phase 3	Recombinant protein vaccine	RSV F protein (fusion protein)
[89Zr]Zr-crefmirlimab berdoxam	89zr-zr-crefmirlimab-berdoxam	Pfizer	marketed	Radiolabeled Monoclonal Antibody	Fibroblast Activation Protein (FAP)	Not specified
Venetoclax; Rituximab	venetoclax-rituximab	Pfizer	marketed	BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)	BCL-2 (venetoclax); CD20 (rituximab)	N/A
Hympavzi	MARSTACIMAB	Pfizer Inc	marketed	Monoclonal Antibody	Factor Xa	2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

Pfizer · 7 drugs in this class
argenx · 7 drugs in this class
Johnson & Johnson · 2 drugs in this class
German CLL Study Group · 2 drugs in this class
Amgen · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Brii Biosciences Limited · 2 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Biotest · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RSVpreF MDV — Competitive Intelligence Brief. https://druglandscape.com/ci/rsvpref-mdv. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab